Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 30% ± 8% | |
glutamatergic neuron | 3 studies | 28% ± 6% | |
transit amplifying cell | 3 studies | 39% ± 15% | |
astrocyte | 3 studies | 29% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 468.40 | 1444 / 1445 | 100% | 18.23 | 183 / 183 |
breast | 100% | 450.39 | 459 / 459 | 99% | 11.76 | 1111 / 1118 |
uterus | 100% | 564.41 | 170 / 170 | 99% | 16.54 | 456 / 459 |
lung | 100% | 419.55 | 576 / 578 | 99% | 10.63 | 1145 / 1155 |
intestine | 100% | 464.03 | 966 / 966 | 99% | 10.99 | 520 / 527 |
bladder | 100% | 432.90 | 21 / 21 | 98% | 11.06 | 494 / 504 |
stomach | 98% | 306.36 | 353 / 359 | 99% | 13.28 | 284 / 286 |
brain | 99% | 305.71 | 2613 / 2642 | 99% | 8.30 | 695 / 705 |
thymus | 100% | 503.53 | 653 / 653 | 97% | 6.10 | 589 / 605 |
skin | 100% | 800.71 | 1805 / 1809 | 96% | 12.37 | 452 / 472 |
ovary | 100% | 651.68 | 180 / 180 | 95% | 5.99 | 409 / 430 |
pancreas | 99% | 308.58 | 325 / 328 | 95% | 5.18 | 169 / 178 |
adrenal gland | 97% | 341.61 | 251 / 258 | 87% | 4.14 | 201 / 230 |
kidney | 97% | 240.29 | 86 / 89 | 87% | 4.84 | 785 / 901 |
prostate | 100% | 421.35 | 245 / 245 | 80% | 2.94 | 404 / 502 |
liver | 85% | 138.42 | 193 / 226 | 55% | 2.89 | 224 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.99 | 29 / 29 |
spleen | 100% | 647.25 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 18.10 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.44 | 1 / 1 |
blood vessel | 100% | 364.20 | 1332 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 454.54 | 1201 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 593.71 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 94% | 234.12 | 812 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 84% | 631.08 | 781 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 59% | 2.27 | 47 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006325 | Biological process | chromatin organization |
GO_2000134 | Biological process | negative regulation of G1/S transition of mitotic cell cycle |
GO_2000773 | Biological process | negative regulation of cellular senescence |
GO_0030154 | Biological process | cell differentiation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0043550 | Biological process | regulation of lipid kinase activity |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_1990841 | Molecular function | promoter-specific chromatin binding |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RBL1 |
Protein name | RB transcriptional corepressor like 1 RBL1 protein Retinoblastoma-like protein 1 (107 kDa retinoblastoma-associated protein) (p107) (pRb1) |
Synonyms | |
Description | FUNCTION: Key regulator of entry into cell division . Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation (By similarity). Recruits and targets histone methyltransferases KMT5B and KMT5C, leading to epigenetic transcriptional repression (By similarity). Controls histone H4 'Lys-20' trimethylation (By similarity). Probably acts as a transcription repressor by recruiting chromatin-modifying enzymes to promoters (By similarity). Potent inhibitor of E2F-mediated trans-activation . May act as a tumor suppressor . . |
Accessions | P28749 ENST00000527999.1 E9PNB6 ENST00000525052.1 Q8WVU8 H0YE05 ENST00000373664.8 [P28749-1] ENST00000344359.7 [P28749-2] |